B and Lester Crawford (Eye On FDA)
The Minneapolis Star Tribune and Associated Press have reported that "Lester Crawford is stating that there was no attempt to disallow Plan B's switch from RX to OTC, but rather that he delayed the switch with the idea that the agency would have by now acted, he said in testimony," writes blogger Mark Senak. In his entry, Senak discusses the questions raised by Crawford's actions.
Drug Sales Slipping Why, and What Can be Done? (Pharma Marketing Blog)
Manufacturers of erectile dysfunction (ED) drugs have retooled their marketing campaigns in the wake of a sales slump. In his entry, blogger John Mack writes about the factors contributing to this slump.